Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2003
10/02/2003WO2003080021A2 Formulation comprising buprenorphine
10/02/2003WO2003080020A1 Heat-reversible composition treating hyposalia and asialia
10/02/2003WO2003079993A2 hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
10/02/2003WO2003079991A2 Method for administration of growth hormone via pulmonary delivery
10/02/2003WO2003079981A2 Bioadhesive drug delivery system
10/02/2003WO2003079972A2 Active agent delivery systems and methods for protecting and administering active agents
10/02/2003WO2003079885A2 Inhalable sustained therapeutic formulations
10/02/2003WO2003070177A3 Use of melatonin analogues for induction of general anesthesia
10/02/2003WO2003061629A3 Dna dosage forms
10/02/2003WO2003061577A3 Polyalkylene glycol with moiety for conjugating biologically active compound
10/02/2003WO2003050257A3 Targeting leukemia cells
10/02/2003WO2003017972A3 Multi-component polymeric systems with reverse thermal gelation behaviour (e.g. peo-ppo copolymers)
10/02/2003WO2003013593A3 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder
10/02/2003WO2003006065A3 Pna conjugate for the treatment of diseases associated with hiv
10/02/2003WO2002096935A3 Long lasting fusion peptide inhibitors for hiv infection
10/02/2003WO2002074323A3 Using neural thread proteins to treat tumors and other hyperproliferative disorders
10/02/2003WO2002069944A3 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
10/02/2003WO2002066016A3 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine
10/02/2003WO2002064158A3 Use of a conjugate of il-6 and the receptor thereof for inducing cellular expression of scf and flt-3l
10/02/2003WO2002056839A3 Pearlescent agent
10/02/2003WO2002042432A3 Epothilone resistant cell lines
10/02/2003WO2002007670A3 Intracellular delivery system for protein phosphatases
10/02/2003WO2002005782A3 Stable salts of o-acetylsalicyclic with basic amino acids
10/02/2003WO2002000243A3 Stabilized interleukin 2
10/02/2003WO2001005355A3 Formulations for il-11
10/02/2003US20030187226 Process of high purity albumin production
10/02/2003US20030187167 Adjusting bulk density; compact tableting
10/02/2003US20030187122 Polymerization of vinyl acetate polymer in presenc eof free radical catalyst
10/02/2003US20030187115 Hydrogel adhesives for use on hair or fiber-populated surfaces
10/02/2003US20030187062 Paclitaxel-based antitumor formulation
10/02/2003US20030187048 Topical applying to skin disorders; aqueous solution
10/02/2003US20030187021 Treatment of CNS disorders using CNS target modulators
10/02/2003US20030187019 Mixing drug with arginine; reduction of bitter taste
10/02/2003US20030186990 Prodrugs of hiv replication inhibiting pyrimidines
10/02/2003US20030186957 Methods of treatment and formulations of cephalosporin
10/02/2003US20030186954 Administering estriol
10/02/2003US20030186952 Anticholesterol agents; cardiovascular disorders
10/02/2003US20030186951 Compositions and methods for enhancing corticosteroid delivery
10/02/2003US20030186933 Preparation of aqueous clear solution dosage forms with bile acids
10/02/2003US20030186909 Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
10/02/2003US20030186902 Use of a pituitary tumor transforming gene peptide which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner
10/02/2003US20030186897 Derivatives of branched-chain lipophilic molecules and uses thereof
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186893 Purified lh
10/02/2003US20030186890 Amphipathic linear peptides and formulations containing said peptides
10/02/2003US20030186874 Genetic enhancers comprising amino acid sequences derived from retrovirus envelope proteins coupled to core peptides, used as drugs having improve half life
10/02/2003US20030186869 Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
10/02/2003US20030186863 For production of peptidomimetic drugs that modulate a large class of proteins involved in signal transduction pathways and oncogenesis
10/02/2003US20030186845 Compositions for preventing urinary calculus
10/02/2003US20030186386 Interleukin 10
10/02/2003US20030186271 Pharmaceutical compositions in particulate form
10/02/2003US20030186191 Dispensing apparatus and cartridge
10/02/2003US20030185901 Methods of treating conditions with a metal-containing material
10/02/2003US20030185894 Process for producing nanoparticles of paclitaxel and albumin
10/02/2003US20030185893 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
10/02/2003US20030185891 Glycogen phosphorylase inhibitor
10/02/2003US20030185890 Compositions and methods for polynucleotide delivery
10/02/2003US20030185888 Volume efficient controlled release dosage form
10/02/2003US20030185879 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
10/02/2003US20030185877 Method of producing oily suspensions of water-soluble vitamins
10/02/2003US20030185873 Provides reversible local anesthesia when implanted or injected in a patient, and a non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia
10/02/2003US20030185870 Oligopeptide binding agent including a first ligand that specifically binds a non-biological substrate and a second ligand that specifically binds a biological substrate.
10/02/2003US20030185869 Having lysozyme adsorbed onto or associated with the surface of an active agent
10/02/2003US20030185843 Heat shock protein-based vaccines and immunotherapies
10/02/2003US20030185842 Heat shock protein-based vaccines and immunotherapies
10/02/2003US20030185834 Administering an anti-angiogenesis factor to localize in the choroidal neovasculature; administering photosensitizer; photodynamic therapy by irradiating with laser light
10/02/2003US20030185832 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker.
10/02/2003US20030185825 Novel immunotoxins and methods of inducing immune tolerance
10/02/2003US20030185816 Modified immunogenic self-protein and a surfactant capable of acting as a solubiliser, especially modified human TNF alpha and cetylpyridinium chloride
10/02/2003US20030185795 G-CSF molecules to which three or more polymer molecules are attached (especially polyethylene glycol) to provide resistance against proteolysis and to allow uptake into the blood stream from the intestine.
10/02/2003US20030185793 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
10/02/2003US20030185788 Guanidinium moieties that are either contiguous or spaced along a polymeric backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface
10/02/2003US20030185772 Alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent.
10/02/2003US20030185762 Aerosol is produced by an electrohydrodynamic spraying device; aqueous carrier vehicle
10/02/2003CA2480417A1 Diclofenac sodium oral pharmaceutical
10/02/2003CA2480334A1 Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450
10/02/2003CA2480007A1 Topical composition based on ion-exchange resins, in particular for treating erythemas
10/02/2003CA2480005A1 Heat-reversible composition treating hyposalia and asialia
10/02/2003CA2479748A1 Fine particle size pioglitazone
10/02/2003CA2479718A1 Analgesics for nasal administration
10/02/2003CA2479576A1 Antibody that binds to a dimer of a prion protein for the treatment of tse infection
10/02/2003CA2479383A1 Storage stable eplerenone formulation
10/02/2003CA2479306A1 Egfr ligands and methods of use
10/02/2003CA2479260A1 Use of sulfoalkyl ether cyclodextrin as a preservative
10/02/2003CA2479252A1 Sustained release formulation of tramadol
10/02/2003CA2478974A1 Inhalable sustained therapeutic formulations
10/02/2003CA2478801A1 Method for administration of growth hormone via pulmonary delivery
10/02/2003CA2478327A1 Hgh (human growth hormone) formulations for pulmonary administration
10/02/2003CA2477088A1 Active agent delivery systems and methods for protecting and administering active agents
10/02/2003CA2475529A1 Methods for treating chronic obstructive pulmonary disease (copd)
10/01/2003EP1348452A1 Surface mineralized spinal implants
10/01/2003EP1348444A2 Sustained release formulation of a peptide complexed with a polymer
10/01/2003EP1348436A1 Meloxicam suppositories
10/01/2003EP1348432A1 Cyclodextrin-containing pharmaceutical preparation
10/01/2003EP1348431A1 Process for producing nanoparticles of paclitaxel and albumin
10/01/2003EP1348430A1 Improved paclitaxel-based antitumor formulation
10/01/2003EP1348429A2 Melt-extruded orally administrable opioid formulations
10/01/2003EP1348427A1 Ophthalmic compositions containing galactomannan polymers and borate
10/01/2003EP1348425A1 Hydrogel adhesives for use on hair or fiber-populated surfaces
10/01/2003EP1348026A2 Fibrin binding moieties useful as imaging agents
1 ... 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 ... 1712